A
Agilent Technologies, Inc.
Price Chart
Latest Quote
$135.39
Current Price| Previous Close | $133.85 |
| Open | $132.63 |
| Day High | $135.56 |
| Day Low | $132.12 |
| Volume | 1,487,594 |
Stock Information
| Quarterly Dividend / Yield | $1.02 / 0.76% |
| Shares Outstanding | 283.50M |
| Total Debt | $3.54B |
| Cash Equivalents | $1.79B |
| Revenue | $6.95B |
| Net Income | $1.30B |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $38.38B |
| P/E Ratio | 29.69 |
| EPS (TTM) | $4.56 |
| Exchange | NYQ |
📊 Custom Metrics & Score
Score: 13/42| Debt to Equity | 0.50 |
| Debt to Earnings | 0.92 |
| Current Ratio | 1.96 |
| Quick Ratio | 1.40 |
| Avg Revenue Growth | 0.37% |
| Profit Margin | 18.75% |
| Return on Equity | 19.33% |
| Avg FCF Growth | 3.21% |
| FCF Yield | 3.00% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $135.39 | 1,149,426 |
| 2026-01-30 | $133.85 | 1,808,000 |
| 2026-01-29 | $133.27 | 1,919,100 |
| 2026-01-28 | $133.87 | 1,682,600 |
| 2026-01-27 | $135.95 | 1,422,500 |
| 2026-01-26 | $135.65 | 1,551,900 |
| 2026-01-23 | $135.05 | 1,811,600 |
| 2026-01-22 | $138.63 | 1,453,200 |
| 2026-01-21 | $139.77 | 1,988,100 |
| 2026-01-20 | $135.83 | 3,300,700 |
| 2026-01-16 | $139.64 | 2,603,400 |
| 2026-01-15 | $144.83 | 1,675,000 |
| 2026-01-14 | $145.92 | 1,684,100 |
| 2026-01-13 | $146.32 | 2,593,400 |
| 2026-01-12 | $147.99 | 1,127,900 |
| 2026-01-09 | $148.52 | 1,818,800 |
| 2026-01-08 | $145.76 | 1,728,700 |
| 2026-01-07 | $147.81 | 2,279,000 |
| 2026-01-06 | $147.60 | 2,627,700 |
| 2026-01-05 | $142.67 | 2,981,500 |
About Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
📰 Latest News
Is Now The Time To Look At Buying Agilent Technologies, Inc. (NYSE:A)?
Simply Wall St. • 2026-01-30T12:00:12Z
ResMed (RMD) Q2 Earnings and Revenues Beat Estimates
Zacks • 2026-01-29T22:20:02Z
Assessing Agilent Technologies (A) Valuation After New AI Slide Scanner Launch In Europe
Simply Wall St. • 2026-01-24T20:10:40Z
Will Agilent’s AI-Enabled Digital Pathology Push Reshape Agilent Technologies' (A) Diagnostics Narrative?
Simply Wall St. • 2026-01-24T16:07:05Z
Is It Time To Reconsider Agilent Technologies (A) After Recent Share Price Weakness
Simply Wall St. • 2026-01-24T11:10:10Z
Analysts consider potential Qiagen deal amid reported strategic review
Investing.com • 2026-01-23T21:20:01ZPBH vs. A: Which Stock Is the Better Value Option?
Zacks • 2026-01-23T16:40:03Z
Agilent Technologies (NYSE:A) sheds 4.2% this week, as yearly returns fall more in line with earnings growth
Simply Wall St. • 2026-01-22T12:02:18Z
Earnings Preview: What to Expect From Agilent Technologies' Report
Barchart • 2026-01-21T12:03:54Z
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino’s Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More
24/7 Wall St. • 2026-01-20T12:55:07Z
Income Statement (Annual)
Revenue
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $3,305,000,000 | $2,975,000,000 | $3,368,000,000 | $3,126,000,000 |
| Cost Of Revenue | $3,305,000,000 | $2,975,000,000 | $3,368,000,000 | $3,126,000,000 |
| Total Revenue | $6,948,000,000 | $6,510,000,000 | $6,833,000,000 | $6,848,000,000 |
| Operating Revenue | $6,948,000,000 | $6,510,000,000 | $6,833,000,000 | $6,848,000,000 |
Expenses
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Interest Expense | $112,000,000 | $96,000,000 | $95,000,000 | $84,000,000 |
| Total Expenses | $5,469,000,000 | $5,022,000,000 | $5,483,000,000 | $5,230,000,000 |
| Other Income Expense | $6,000,000 | $49,000,000 | $33,000,000 | $-39,000,000 |
| Other Non Operating Income Expenses | $6,000,000 | $49,000,000 | $33,000,000 | $-39,000,000 |
| Net Non Operating Interest Income Expense | $-50,000,000 | $-16,000,000 | $-44,000,000 | $-75,000,000 |
| Interest Expense Non Operating | $112,000,000 | $96,000,000 | $95,000,000 | $84,000,000 |
| Operating Expense | $2,164,000,000 | $2,047,000,000 | $2,115,000,000 | $2,104,000,000 |
Income & Earnings
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Net Interest Income | $-50,000,000 | $-16,000,000 | $-44,000,000 | $-75,000,000 |
| Interest Income | $62,000,000 | $80,000,000 | $51,000,000 | $9,000,000 |
| Normalized Income | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Net Income From Continuing And Discontinued Operation | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Total Operating Income As Reported | $1,479,000,000 | $1,488,000,000 | $1,350,000,000 | $1,618,000,000 |
| Net Income Common Stockholders | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Net Income | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Net Income Including Noncontrolling Interests | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Net Income Continuous Operations | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Pretax Income | $1,435,000,000 | $1,521,000,000 | $1,339,000,000 | $1,504,000,000 |
| Interest Income Non Operating | $62,000,000 | $80,000,000 | $51,000,000 | $9,000,000 |
| Operating Income | $1,479,000,000 | $1,488,000,000 | $1,350,000,000 | $1,618,000,000 |
| Gross Profit | $3,643,000,000 | $3,535,000,000 | $3,465,000,000 | $3,722,000,000 |
Per Share Metrics
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Diluted EPS | - | $4.43 | $4.19 | $4.18 |
| Basic EPS | - | $4.44 | $4.22 | $4.19 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,835,000,000 | $1,874,000,000 | $1,705,000,000 | $1,905,000,000 |
| Reconciled Depreciation | $288,000,000 | $257,000,000 | $271,000,000 | $317,000,000 |
| EBITDA (Bullshit earnings) | $1,835,000,000 | $1,874,000,000 | $1,705,000,000 | $1,905,000,000 |
| EBIT | $1,547,000,000 | $1,617,000,000 | $1,434,000,000 | $1,588,000,000 |
| Diluted NI Availto Com Stockholders | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Tax Provision | $132,000,000 | $232,000,000 | $99,000,000 | $250,000,000 |
| Research And Development | $455,000,000 | $479,000,000 | $481,000,000 | $467,000,000 |
| Selling General And Administration | $1,709,000,000 | $1,568,000,000 | $1,634,000,000 | $1,637,000,000 |
| Diluted Average Shares | - | $291,000,000 | $296,000,000 | $300,000,000 |
| Basic Average Shares | - | $290,000,000 | $294,000,000 | $299,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Tangible Assets | $1,823,000,000 | $874,000,000 | $1,410,000,000 | $532,000,000 |
| Total Assets | $12,727,000,000 | $11,846,000,000 | $10,763,000,000 | $10,532,000,000 |
| Total Non Current Assets | $8,133,000,000 | $7,887,000,000 | $6,577,000,000 | $6,754,000,000 |
| Other Non Current Assets | $1,059,000,000 | $910,000,000 | $708,000,000 | $686,000,000 |
| Goodwill And Other Intangible Assets | $4,918,000,000 | $5,024,000,000 | $4,435,000,000 | $4,773,000,000 |
| Other Intangible Assets | $445,000,000 | $547,000,000 | $475,000,000 | $821,000,000 |
| Current Assets | $4,594,000,000 | $3,959,000,000 | $4,186,000,000 | $3,778,000,000 |
| Other Current Assets | $293,000,000 | $334,000,000 | $274,000,000 | $282,000,000 |
| Inventory | $1,025,000,000 | $972,000,000 | $1,031,000,000 | $1,038,000,000 |
| Receivables | $1,487,000,000 | $1,324,000,000 | $1,291,000,000 | $1,405,000,000 |
| Accounts Receivable | $1,487,000,000 | $1,324,000,000 | $1,291,000,000 | $1,405,000,000 |
| Cash Cash Equivalents And Short Term Investments | $1,789,000,000 | $1,329,000,000 | $1,590,000,000 | $1,053,000,000 |
| Cash And Cash Equivalents | $1,789,000,000 | $1,329,000,000 | $1,590,000,000 | $1,053,000,000 |
Debt
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Debt | $1,565,000,000 | $2,061,000,000 | $1,145,000,000 | $1,716,000,000 |
| Total Debt | $3,354,000,000 | $3,390,000,000 | $2,735,000,000 | $2,769,000,000 |
| Long Term Debt And Capital Lease Obligation | $3,050,000,000 | $3,345,000,000 | $2,735,000,000 | $2,733,000,000 |
| Long Term Debt | $3,050,000,000 | $3,345,000,000 | $2,735,000,000 | $2,733,000,000 |
| Current Debt And Capital Lease Obligation | $304,000,000 | $45,000,000 | - | $36,000,000 |
| Current Debt | $304,000,000 | $45,000,000 | - | $36,000,000 |
Liabilities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $5,986,000,000 | $5,948,000,000 | $4,918,000,000 | $5,227,000,000 |
| Total Non Current Liabilities Net Minority Interest | $3,639,000,000 | $4,053,000,000 | $3,315,000,000 | $3,366,000,000 |
| Other Non Current Liabilities | $463,000,000 | $578,000,000 | $477,000,000 | $536,000,000 |
| Current Liabilities | $2,347,000,000 | $1,895,000,000 | $1,603,000,000 | $1,861,000,000 |
| Current Deferred Liabilities | $624,000,000 | $544,000,000 | $505,000,000 | $461,000,000 |
| Payables And Accrued Expenses | $976,000,000 | $938,000,000 | $727,000,000 | $909,000,000 |
| Payables | $570,000,000 | $540,000,000 | $418,000,000 | $580,000,000 |
| Accounts Payable | $570,000,000 | $540,000,000 | $418,000,000 | $580,000,000 |
Equity
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Common Stock Equity | $6,741,000,000 | $5,898,000,000 | $5,845,000,000 | $5,305,000,000 |
| Total Equity Gross Minority Interest | $6,741,000,000 | $5,898,000,000 | $5,845,000,000 | $5,305,000,000 |
| Stockholders Equity | $6,741,000,000 | $5,898,000,000 | $5,845,000,000 | $5,305,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-226,000,000 | $-305,000,000 | $-327,000,000 | $-347,000,000 |
| Other Equity Adjustments | $-226,000,000 | $-305,000,000 | $-327,000,000 | $-347,000,000 |
| Retained Earnings | $1,389,000,000 | $750,000,000 | $782,000,000 | $324,000,000 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $283,054,377 | $285,193,011 | $292,123,241 | $295,000,000 |
| Share Issued | $283,054,377 | $285,193,011 | $292,123,241 | $295,000,000 |
| Tangible Book Value | $1,823,000,000 | $874,000,000 | $1,410,000,000 | $532,000,000 |
| Invested Capital | $10,095,000,000 | $9,288,000,000 | $8,580,000,000 | $8,074,000,000 |
| Working Capital | $2,247,000,000 | $2,064,000,000 | $2,583,000,000 | $1,917,000,000 |
| Total Capitalization | $9,791,000,000 | $9,243,000,000 | $8,580,000,000 | $8,038,000,000 |
| Additional Paid In Capital | $5,575,000,000 | $5,450,000,000 | $5,387,000,000 | $5,325,000,000 |
| Capital Stock | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Common Stock | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $126,000,000 | $130,000,000 | $103,000,000 | $97,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $126,000,000 | $130,000,000 | $103,000,000 | $97,000,000 |
| Current Deferred Revenue | $624,000,000 | $544,000,000 | $505,000,000 | $461,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $443,000,000 | $368,000,000 | $371,000,000 | $455,000,000 |
| Current Accrued Expenses | $406,000,000 | $398,000,000 | $309,000,000 | $329,000,000 |
| Investments And Advances | $133,000,000 | $175,000,000 | $164,000,000 | $195,000,000 |
| Goodwill | $4,473,000,000 | $4,477,000,000 | $3,960,000,000 | $3,952,000,000 |
| Net PPE | $2,023,000,000 | $1,778,000,000 | $1,270,000,000 | $1,100,000,000 |
| Accumulated Depreciation | $-1,423,000,000 | $-1,304,000,000 | $-1,223,000,000 | $-1,148,000,000 |
| Gross PPE | $3,446,000,000 | $3,082,000,000 | $2,493,000,000 | $2,248,000,000 |
| Machinery Furniture Equipment | $1,321,000,000 | $1,227,000,000 | $1,024,000,000 | $934,000,000 |
| Buildings And Improvements | $2,056,000,000 | $1,786,000,000 | $1,409,000,000 | $1,255,000,000 |
| Land And Improvements | $69,000,000 | $69,000,000 | $60,000,000 | $59,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $547,000,000 | $523,000,000 | $570,000,000 | $555,000,000 |
| Raw Materials | $478,000,000 | $449,000,000 | $461,000,000 | $483,000,000 |
| Other Short Term Investments | - | - | - | $0 |
| Commercial Paper | - | - | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | $1,152,000,000 | $1,373,000,000 | $1,474,000,000 | $1,021,000,000 |
Operating Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Operating Cash Flow | $1,559,000,000 | $1,751,000,000 | $1,772,000,000 | $1,312,000,000 |
| Cash Flow From Continuing Operating Activities | $1,559,000,000 | $1,751,000,000 | $1,772,000,000 | $1,312,000,000 |
| Operating Gains Losses | $36,000,000 | $-6,000,000 | $-2,000,000 | $76,000,000 |
Investing Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Capital Expenditure | $-407,000,000 | $-378,000,000 | $-298,000,000 | $-291,000,000 |
| Investing Cash Flow | $-394,000,000 | $-1,258,000,000 | $-310,000,000 | $-338,000,000 |
| Cash Flow From Continuing Investing Activities | $-394,000,000 | $-1,258,000,000 | $-310,000,000 | $-338,000,000 |
| Net Other Investing Changes | $1,000,000 | $-13,000,000 | $-8,000,000 | $-4,000,000 |
Financing Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-425,000,000 | $-1,150,000,000 | $-575,000,000 | $-1,139,000,000 |
| Financing Cash Flow | $-715,000,000 | $-752,000,000 | $-930,000,000 | $-1,372,000,000 |
| Cash Flow From Continuing Financing Activities | $-715,000,000 | $-752,000,000 | $-930,000,000 | $-1,372,000,000 |
| Net Other Financing Charges | $-39,000,000 | $-42,000,000 | $-122,000,000 | $-67,000,000 |
| Cash Dividends Paid | $-282,000,000 | $-274,000,000 | $-265,000,000 | $-250,000,000 |
| Common Stock Dividend Paid | $-282,000,000 | $-274,000,000 | $-265,000,000 | $-250,000,000 |
| Net Common Stock Issuance | $-425,000,000 | $-1,150,000,000 | $-575,000,000 | $-1,139,000,000 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-3,000,000 | $-600,000,000 | $0 | $-609,000,000 |
| Issuance Of Debt | $4,000,000 | $1,197,000,000 | $0 | $600,000,000 |
| Interest Paid Supplemental Data | $101,000,000 | $80,000,000 | $89,000,000 | $85,000,000 |
| Income Tax Paid Supplemental Data | $318,000,000 | $314,000,000 | $199,000,000 | $279,000,000 |
| End Cash Position | $1,791,000,000 | $1,332,000,000 | $1,593,000,000 | $1,056,000,000 |
| Beginning Cash Position | $1,332,000,000 | $1,593,000,000 | $1,056,000,000 | $1,490,000,000 |
| Effect Of Exchange Rate Changes | $9,000,000 | $-2,000,000 | $5,000,000 | $-36,000,000 |
| Changes In Cash | $450,000,000 | $-259,000,000 | $532,000,000 | $-398,000,000 |
| Proceeds From Stock Option Exercised | $72,000,000 | $77,000,000 | $67,000,000 | $58,000,000 |
| Common Stock Payments | $-425,000,000 | $-1,150,000,000 | $-575,000,000 | $-1,139,000,000 |
| Net Issuance Payments Of Debt | $-41,000,000 | $637,000,000 | $-35,000,000 | $26,000,000 |
| Net Short Term Debt Issuance | $-42,000,000 | $40,000,000 | $-35,000,000 | $35,000,000 |
| Net Long Term Debt Issuance | $1,000,000 | $597,000,000 | $0 | $-9,000,000 |
| Long Term Debt Payments | $-3,000,000 | $-600,000,000 | $0 | $-609,000,000 |
| Long Term Debt Issuance | $4,000,000 | $1,197,000,000 | $0 | $600,000,000 |
| Net Investment Purchase And Sale | $8,000,000 | $-5,000,000 | $-3,000,000 | $9,000,000 |
| Sale Of Investment | $8,000,000 | $0 | $5,000,000 | $22,000,000 |
| Purchase Of Investment | $0 | $-5,000,000 | $-8,000,000 | $-13,000,000 |
| Net Business Purchase And Sale | $4,000,000 | $-862,000,000 | $-1,000,000 | $-52,000,000 |
| Sale Of Business | $4,000,000 | $0 | $50,000,000 | $0 |
| Net PPE Purchase And Sale | $-407,000,000 | $-378,000,000 | $-298,000,000 | $-291,000,000 |
| Purchase Of PPE | $-407,000,000 | $-378,000,000 | $-298,000,000 | $-291,000,000 |
| Change In Working Capital | $-131,000,000 | $83,000,000 | $-116,000,000 | $-478,000,000 |
| Change In Other Working Capital | $99,000,000 | $-61,000,000 | $-44,000,000 | $-30,000,000 |
| Change In Payables And Accrued Expense | $16,000,000 | $103,000,000 | $-171,000,000 | $121,000,000 |
| Change In Payable | $16,000,000 | $103,000,000 | $-171,000,000 | $121,000,000 |
| Change In Account Payable | $16,000,000 | $103,000,000 | $-171,000,000 | $121,000,000 |
| Change In Inventory | $-97,000,000 | $34,000,000 | $-33,000,000 | $-248,000,000 |
| Change In Receivables | $-149,000,000 | $7,000,000 | $132,000,000 | $-321,000,000 |
| Changes In Account Receivables | $-149,000,000 | $7,000,000 | $132,000,000 | $-321,000,000 |
| Other Non Cash Items | $50,000,000 | $44,000,000 | $47,000,000 | $10,000,000 |
| Stock Based Compensation | $128,000,000 | $129,000,000 | $111,000,000 | $125,000,000 |
| Asset Impairment Charge | $15,000,000 | $19,000,000 | $277,000,000 | $0 |
| Deferred Tax | $-130,000,000 | $-64,000,000 | $-56,000,000 | $8,000,000 |
| Deferred Income Tax | $-130,000,000 | $-64,000,000 | $-56,000,000 | $8,000,000 |
| Depreciation Amortization Depletion | $288,000,000 | $257,000,000 | $271,000,000 | $317,000,000 |
| Depreciation And Amortization | $288,000,000 | $257,000,000 | $271,000,000 | $317,000,000 |
| Gain Loss On Investment Securities | $36,000,000 | $-6,000,000 | $41,000,000 | $67,000,000 |
| Gain Loss On Sale Of Business | $0 | $0 | $-43,000,000 | $0 |
| Net Income From Continuing Operations | $1,303,000,000 | $1,289,000,000 | $1,240,000,000 | $1,254,000,000 |
| Purchase Of Business | - | $-862,000,000 | $-51,000,000 | $-52,000,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | - | $-1,260,000,000 |
| Short Term Debt Issuance | - | - | - | $1,295,000,000 |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |